Gilead to start trial of inhaled version of Covid-fighting remdesivir
Excerpt from the article:
“Gilead Sciences Inc. is prepping to launch clinical trials of an inhaled form of its Covid-19-fighting drug remdesivir, a version that could expand access to the treatment and keep less-severe patients out of hospitals.
Remdesivir is the only drug granted emergency use authorization from the Food and Drug Administration against the disease, which has killed 469,220 people globally, more than a quarter of those in the United States. The virus that causes the disease has infected over 9 million people worldwide, including nearly 2.3 million U.S. residents.”
Click the button below to read the article:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?